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Abstract
Background: Hypertension continues to be a major burden of public health concern despite the recent advances and proven benefit of pharmacological 
therapy. A certain subset of patients has hypertension resistant to maximal medical therapy and appropriate lifestyle measures. Resistant hypertension 
continues to pose a major challenge to clinicians worldwide and has serious implications for patients who are at increased risk of cardiovascular morbidity 
and mortality with this diagnosis. Pharmacological therapy for resistant hypertension follows guidelines-based regimens, although there is surprisingly 
scant evidence for beneficial outcomes using additional drug treatment after three antihypertensives have failed to achieve target blood pressure. Through 
modulation of renin secretion, glomerular filtration rate and renal absorption of sodium, the sympathetic innervation of the kidneys plays an important 
role in the pathogenesis of hypertension. A novel catheter-based technique for renal sympathetic denervation (RSDN) as a new therapeutic avenue has 
great promise for the treatment of resistant hypertension. Renal denervation has the unique advantage of offering the denervation at the renal level, thus 
mitigating the systemic side effects. Various trials evaluated the role of renal denervation in the management of resistant hypertension and have found 
promising results. More studies are underway to evaluate the role of renal denervation in patients presenting with resistant hypertension in different 
scenarios. 
Conclusions: This review included the physiology of the renal sympathetic nervous system and the renal nerve anatomy. Furthermore, the RSDN procedure, 
technology systems, and RSDN clinical trials as well as findings besides antihypertensive effects were discussed. Findings on safety and efficacy seem to 
suggest that renal sympathetic denervation could be of therapeutic benefit in refractory hypertensive patients. Despite the fast pace of development in 
RSDN therapies, only initial and very limited clinical data are available. Large gaps in knowledge concerning the long-term effects and consequences of 
RSDN still exist, and solid, randomized data are warranted.
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Introduction
Arterial hypertension epidemiology and control
The prevalence of hypertension is high and is growing 
steadily. In 2000, about 1 out of 4 adults (>20 years) were 
affected worldwide, and its prevalence is expected to in-
crease to 1 out of 3 adults, reaching 1.56 billion in 2025 
[1]. Hypertension is an independent major risk factor of 
cardiovascular events as stroke, heart attack, heart failure 
and kidney failure, being responsible for 62% of cerebro-
vascular diseases and 49% of ischemic heart disease [2]. 
Each increase in systolic blood pressure by 20 mmHg and 
diastolic blood pressure by 10 mmHg doubles the rate of 
cardiovascular mortality in 10 years [3].
The American Heart Association [4] and the Joint National 
Committee [5] define resistant hypertension as persistently 
high blood pressure (systolic and diastolic blood pressure>140 
and 90 mmHg, respectively) despite medication administered, 
which includes three antihypertensives of different classes 
in appropriately tolerated maximum doses, one of which is 
a diuretic. It is necessary to cautiously differentiate resistant 
hypertension from uncontrolled hypertension caused by 
sub-optimal pharmacological treatment, non-compliance to 
treatment and secondary hypertension. The prevalence of 
resistant hypertension is often underestimated for various 
reasons, including inadequate sample size and exclusion of 
patients with resistant hypertension from large clinical trials 
[6, 7]. Kaplan et al estimated that up to 5% of patients in ge-
neral clinics and about 50% of patients in clinics for kidney 
diseases suffer from resistant hypertension [6].
Renal sympathetic nervous system and hypertension
Maintenance of normal blood pressure readings is due to 
the coordinated action of several systems, the sympathetic 
nervous system playing an important role among them. The 
increase in sympathetic activity correlates with all hyperten-
sion phenotypes, central sympathetic activity, measured at 
the level of muscular sympathetic activity, being increased 
in all grades of hypertension compared to normotensive 
patients [8].
The important role of the renal sympathetic nervous sys-
tem (SNS) in hypertension initiation and maintenance has 
been demonstrated through animal experiments and human 
experience, either  by measuring its activity in hypertensive 
subjects or by monitoring the changes in blood pressure rea-
dings after sympathetic manipulations [9,10].
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The renal sympathetic nervous system is composed of 
efferent fibers directed from the central nervous system (CNS) 
to kidneys and afferent fibers having an opposite direction. 
The preganglionic axons of neurons, that originate in the 
T10-L2, interact with postganglionic renal nerves at the level 
of sympathetic pre- and paravertebral ganglia. Postganglionic 
renal fibers run parallel to the renal arteries, located around 
the adventitia and enter through the renal hilum to innervate 
renal tubules, blood vessels and the juxtaglomerular apparatus 
[11] (fig. 1).
By increasing the production of norepinephrine, these 
efferent fibers transmit stimuli from the CNS to kidneys and 
contribute to volumetric homeostasis and blood pressure va-
lues, facilitating tubular reabsorption of sodium, followed by 
hydrosaline retention, and renin secretion, further stimulating 
the renin-angiotensin-aldosterone system, renal vasoconstric-
tion with the subsequent reduction of the renal blood flow [11, 
12, 13, 14]. Oppositely, the kidneys transmit neural responses 
to the CNS through afferent fibers, also located around the 
adventitia of renal arteries [15, 16, 17]. 
Afferent renal sympathetic fibers have an extensive network 
in the renal pelvis and transmit signals from two types of recep-
tors: mechanical-sensitive receptors that respond to increase 
in hydrostatic pressure and chemosensitive receptors that are 
activated by hypoxia and renal ischemia. The signals from these 
receptors pass through ipsilateral dorsal ganglia to the CNS, espe-
cially to the paraventricular nucleus of the hypothalamus [16, 18]. 
This stimulation of the afferent nervous system leads to increase 
in blood pressure readings through release of vasopressin, and 
increase in the systemic vascular resistance. In addition, afferent 
fibers communicate with the contralateral kidney, thus balancing 
the unilateral impairment of hydrosaline excretion, underlying 
the reno-renal reflux [19].
Previous experience of lumbar sympathectomy in the 
treatment of hypertension
Recognition of the important role that the sympathetic 
nervous system plays in the pathogenesis of hypertension 
has led to the development of a surgical approach, known as 
radical lumbar-dorsal splanchectomy, which interrupts the 
release of catecholamines [20]. This technique, developed 
by Smithwick in 1938, reduced blood pressure readings  and 
mortality, but led to severe unacceptable side effects [20, 21]. 
Several uncontrolled clinical trials on surgical sympathec-
tomy have shown a significant decrease in blood pressure, 
reduction of heart size, improvement of the renal function 
and a lower rate of cerebrovascular events [22]. However, the 
beneficial effects were counteracted by the severe orthostatic 
hypotension, and the evolution of antihypertensive drugs 
favored lumbar sympathectomy to be generally removed from 
medical practice in 1975.
Technique of Renal Sympathetic Denervation (RSDN)
Sobotka and Esler (pioneers in percutaneous renal artery 
sympathetic denervation) conducted the first studies of ca-
theter-based renal ablation, using radio frequency energy. 
This procedure involves insertion of an endovascular catheter 
under fluoroscopic guidance through the femoral artery and 
its advancement towards a distal renal artery. Sympathetic 
nerve ablation was performed due to radiofrequency energy 
applied through an electrode located on the tip of the endo-
vascular catheter. Thus, there were selective thermal injuries 
at the level of renal sympathetic nerves, while abdominal, 
pelvic and lower limbs nerves were not affected. Multiple 
radiofrequency treatments were applied circumferentially, 
initially in the distal renal artery, and then proximally with 
catheter withdrawal. The energy applied was lower than that 
used in electrophysiological studies on the heart; the entire 
Fig. 1.  Anatomy of renal nerves: postganglionic renal fibers running parallel to renal arteries,  
primarily situated around the adventitia.
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procedure lasting 30-60 minutes. Selection of patients to be 
subjected to RSDN is quite scrupulous. 
Table 1 shows the main eligibility and exclusion criteria 
in all clinical studies conducted to date.
Table 1
Eligibility and exclusion criteria in RSDN clinical trials
Eligibility criteria Exclusion criteria
1. Office SBP≥160mmHg 
(≥150mmHgin type 2 di-
abetes), when administe-
ring ≥3antihypertensives 
at maximum tolerated 
doses (including a 
diuretic).
1. Secondary hypertension
2. Pseudoresistence
3. Impaired renal function (GFR≤ 45 
ml/min/1.73 m2)
4. Renovascular abnormalities: acces-
sory arteries, renal artery stenosis, 
previous revascularization
5. Pregnancy
6. Type 1diabetes
7. The presence of permanent pace-
maker or implantable cardioverter 
defibrillator
8. Myocardial infarction, unstable 
angina or stroke in the previous six 
months
Note: SBP - systolic blood pressure.
It is to be noted that the main renal artery must have 
a length ≥ 20 mm and have a diameter ≥ 4 mm to avoid 
structural damage to the arterial wall. Relative contra-
indications for performing RSDN include visible renal 
artery stenosis, calcification or atherosclerotic plaque and 
multiple renal arteries which supply the upper and lower 
poles of the kidney.
Renal artery denervation in patients with resistant 
hypertension, using a standard electrophysiology catheter, 
showed a significant reduction in blood pressure [23]. 
These data led to the development of numerous catheter 
systems that are under clinical evaluation. Currently, four 
systems used in radiofrequency ablation technology have 
been approved for phase III of the clinical trial in the 
US, Europe and other countries: Medtronic's Symplicity, 
St. Jude's EnligHTN, Boston Scientific's Vessix's V2 and 
Covidien's OneShot.
RSDN preclinical data
The importance of the renal sympathetic nervous system 
in hypertension has been suggested; when its increased activity 
was described in rats with spontaneous genetic hypertension 
compared with the normotensive control group [24]. Several 
animal models have been used to study the impact of renal 
sympathetic fibers on blood pressure [25].
In a large research study including more than 300 pigs, a 
significant decrease (p <0.0001) of noradrenaline in the kidney 
tissue was observed in animals subjected to renal denervation 
compared to the control group. The procedure safety was 
verified through angiography, as well as histopathologic and 
clinical data at 7, 30, 60, and 180 days. At all evaluation stages 
the endothelium was confirmed to be intact, while arterial 
stenosis was absent.
RSDN clinical trials
To show RSDN efficacy and safety, several clinical trials 
have been initiated. Thus, in 2009 a clinical trial including 
106 patients was initiated; the number of initiated clinical 
trials reached 49 by 2013, and 6,875 patients were enrolled 
[26] (fig. 2).
The European Society of Cardiology has developed a 
Consensus on selection of patients to be subjected to RSDN 
[27] (fig. 3).
The largest and most important clinical trials according to 
data obtained are considered those conducted by Medtronic 
Company (fig. 4) [28].
Fig. 2.  Annual share of RSDN clinical trials.
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the next 6 months (primary end-point), and lot subjected to 
RSDN [31].
In March 2014, Symplicity HTN-3 trial results were publi-
shed. They appeared to shatter hopes around renal denerva-
tion as a method for the treatment of resistant hypertension. 
The change in office SBP at 6 months was the primary effi-
cacy end-point, while the change in SBP measured by ABPM 
was the secondary end-point. At 6 months follow-up, office 
SBP in patients subjected to RSDN decreased by 14.1 mmHg 
and by 11.7 mmHg in the control group. The difference of 
2.39 mmHg, with p=0.26, was statistically insignificant. The 
change in ambulatory SBP at 6 months was 6.8 mm Hg in the 
denervation group and 4.8 in the control group. The difference 
between the two groups was 1.96, with p=0.98, being also 
statistically insignificant.
However, the study has reached the point of primary safety, 
major adverse effects being recorded in 5 patients (1.4%) in 
the denervation lot and 1 (0.6%) patient in the control lot [32]. 
This study showed no RSDN benefit, although it demonstrated 
its safety. These data contradict the data obtained in previous 
trials that have demonstrated a significant decrease in blood 
pressure after RSDN. The obvious question arose: why were 
the Simplicity HTN-3 trial results so different compared to 
the previous two studies. 
Certain assumptions were issued, namely that patients were 
not adequately stabilized before randomization, given that some 
drugs require more than 8 weeks to achieve maximum effect 
and the follow-up in the study was only 2 weeks. Moreover, in 
this study 40% of patients used direct vasodilators and a higher 
percentage took spironolactone. The patient population included 
in the study constituted another difference. In Simplicity HTN-3 
one third of subjects were African-American, while Caucasians 
predominated in previous studies, being recognized a more 
difficult response of African-American hypertensive patients 
to therapy. Other observations are related to the absence of ran-
domization in HTN-1, and, though HTN-2 was randomized, it 
was not blind [33].
Fig. 3.  Selection of patients to be subjected to RSDN.
Fig. 4.  RSDN clinical trials conducted by Medtronic.
Symplicity HTN-1.  Symplicity HTN-1 was a series of 
pilot studies that included 153 patients. A decrease in blood 
pressure by -22/-10 mmHg at 6 months after procedure, and 
by -32/-14 mmHg at 36 months has been reported [29].
Symplicity HTN-2. Symplicity HTN-2 is the first rando-
mized clinical trial including 106 patients with treatment-
resistant hypertension, that showed a decrease in systolic 
and diastolic blood pressure by -32/-12 mmHg, the beneficial 
effect being maintained for 3 years [30].
Symplicity HTN-3.  Symplicity HTN-3 was first blind 
randomized trial, the results of which were long overdue 
and veridically much higher than those obtained in previous 
studies, taking into account the exclusion of many limitations 
such as small number of the study lot, limited use of ambu-
latory blood pressure monitoring (ABPM), lack of the blind 
control lot, etc. After performing the initial screening, patients 
followed ambulatory treatment with constant blood pressure 
monitoring at home for 2 weeks. 
At the next stage of evaluation, having confirmed treat-
ment-resistant hypertension, renal angiography was perfor-
med. During the procedure, depending on the suitability of 
anatomical eligibility criteria, patients were randomized into 
two lots – control lot that continued to take medication over 
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Symplicity Global Registry study
Symplicity Global Registry study including patients with 
resistant hypertension is underway. It collects data on other 
diseases characterized by increased activity of the SNS such as 
type 2 diabetes, heart and renal failure, obstructive sleep ap-
nea, etc. Enrollment of 5000 patients to be subjected to RSDN 
is expected in 231 international centers in 37 countries. After 
presenting the Symplicity HTN-3trial results, which showed 
RSDN inefficacy compared to placebo, there are preliminary 
data obtained from the Symplicity Global Registry, demon-
strating significant reductions in both office and ambulatory 
SBP after 6 months.
These data were presented at the scientific session of the 
American College of Cardiology on March 30, 2013 [34].
Conclusions
1. Despite the negative results of the Symplicity HTN-3 
trial, it is too early to make conclusions that RSDN therapy 
failed in the management of resistant hypertension.
2. There are sufficient clinical data from multiple clinical 
trials demonstrating positive effects both in lowering blood 
pressure and other diseases associated with increased activity 
of the SNS.
3. A more rigorous selection of patients is necessary to 
perform RSDN, at present the procedure being recommended 
only for patients with resistant hypertension.
4. RSDN is not a “panaceea” in the treatment of patients 
with resistant hypertension.
5. Several large randomized clinical trials are necessary.
6. A cost-effectiveness analysis of RSDN would be wel-
come.
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